always online......
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow....??...CBIS..
22:00:00 MEZ 0,0223 USD 7.100 Stk. +11,50% +0,0023 USD
http://www.wallstreet-online.de/aktien/cannabis-science-aktie
Performance:1 Month CBIS +73,91 %
Quote :0.0216 0.0016 (+8.00%) today...CBIS...
Real-Time Best Bid &Ask 0.0235 /0.0238
Great News from CBIS.....WOW.....
Cannabis Science CEO Excited as Record Date for Gifted Shares Approaches Tomorrow, Thursday, March 31st, 2016, and the New 360,000 Sq. Ft., Nevada Facility Moves to Design Phase
COLORADO SPRINGS, CO -- (Marketwired) -- 03/30/16 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, has announced that the Cannabis Science CEO is excited as record date for gifted shares approaches fast, tomorrow, Thursday, March 31st, 2016, and the new 360,000 sq. ft. facility in Nevada moves into design phase.
The Company will update a secure website platform to include forms for shareholders to report their share ownership and attach any required documentation for transmission directly to Cannabis Science. This will help streamline the process and get shareholders their gifted shares more quickly.
In the same vein as the previously announced 360,000 sq. ft. educational, drug development deal in Nevada has moved into design phase, and the Company has identified other large parcels of land for similar drug development facilities in California. A map of the Nevada facility will be included on the Company website as the Company gets further into the design process and the Company will announce the new land deals in California after signing has been completed.
Cannabis Science has been approached by several investor shareholders and industry professionals looking to expand and capitalize on the Nevada deal. The Company is negotiating with new investors and industry professionals to become a part of the Cannabis Science Research Park, which will help spur new drug research, development, and ultimately manufacturing in addition to scientific contribution and studies.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated bythese forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Cannabis Science Inc.
Teresa Misenheimer
Investor Relations
teresa@cannabisscience.com
Tel: 813-500-7332
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 310.650.3788
Cannabis Science, Inc.
Mr. Robert Kane
Director & CFO
info@cannabisscience.com
Tel: 1.888.889.0888
Source: Cannabis Science, Inc.
OMar. 30, 2016 9:20 AM ET only A Few Public Companies Really Focus On Developing Medical Marijuana: Here's A List
Mar. 30, 2016 9:20 AM ET
|
Includes: CARA, CBIS, CNAB, CNBX, GBLX, GWPH, IMLFF, NMUS, OWCP, OXIS, PMCB, VRCI
Lorin Cohen
Lorin Cohen
?Follow (12 followers)
Growth at reasonable price, micro-cap, small-cap, Cannabis
•Marijuana is the next multi-billion-dollar emerging market.
•Medical marijuana generated $4.2 billion in the US in 2015, forecast to surpass $10 billion by 2020.
•Of the 167 companies listed in the MJIC Global Marijuana Index, only 12 are involved in real medical marijuana research.
Only A Few Public Companies Really Focus On Developing Medical Marijuana - Here's a List
The concept of marijuana as medicine in the modern era is relatively new, despite its 1000s of years of history as a popular treatment for conditions from gout to gonorrhea. That all changed about a century ago when prohibitionists collaborated with politicians to execute one of the most effective smear campaigns ever created, implicating marijuana use in all that was evil in the world. Sadly, some of the tenets of that effort remain part of the general discourse, with many in the US still believing the drive for medical marijuana is simply a plot by recreational users looking to skirt the laws.
We have a young Israeli doctoral student to thank for today's multi-billion-dollar medical marijuana industry. Dr. Raphael Mechoulam - considered by many to be the father of medical marijuana - began investigating cannabis in an effort to determine why it affects us. Working with the help of a grant from NIDA, Mechoulam and his team identified CBD, THC and other cannabinoids in the early sixties, and he hasn't stopped since. In the late 1980s, Dr. Mechoulam's research contributed to another breakthrough, the discovery of the endocannabinoid system, the mechanism through which marijuana effects our health and well-being.
Since that discovery, researchers have determined that, not only is the endocannabinoid system influential in a number of physiological and pathological functions, it appears to have a real impact on the treatment of a range of conditions and diseases, from pain and inflammation to cancer, and many others. While not the panacea that some proponents would have us believe, most scientists agree that cannabis-centric medicine offers substantial potential, which at the very minimum, warrants further research.
Unfortunately, and primarily for political reasons, the vast majority of marijuana research sanctioned in the United States has focused on proving its negative effects, primarily addiction and the degradation of mental capacity. Further, the U.S. still classifies marijuana as a Schedule I narcotic with "no currently accepted medical use and a high potential for abuse." Further, because cannabis remains illegal at the federal, and thus national level, cannabis remains the third rail for traditional pharmaceutical companies, leaving most research to be conducted internationally and through private entities, universities and hospitals.
These obstacles have spawned a market for the development and testing of synthetic cannabinoids. Designed to mimic those found in the cannabis plant and deemed suitable by the FDA and other federal agencies, synthetic cannabinoids have proven to be somewhat effective in treating disease, however the vast majority of cannabis researchers favor investigating the plant's natural components.
The good news is that a handful of scientists are taking up the cause, and they are making headway. This is in large part thanks to the research being conducted in Israel, where the government continues to support marijuana research. And as word of their progress spreads, several U.S. patient populations are calling for change, led at the grass roots by the parents of children suffering from intractable epilepsy and veterans with post-traumatic stress disorder (PTSD). These two groups are hard to ignore, if for no reason other than the potential negative publicity for doing so, and they too are making headway.
In 2015, the FDA loosened the reigns on marijuana research, indicating a willingness to allow research on human subjects. That being said, those who wish to implement clinical trials must still get approval from the FDA, Drug Enforcement Agency and the National Institute on Drug Abuse, so the change did not result in a groundswell of activity.
How To Participate As An Investor
Despite the above-mentioned hurdles to operating in the sector, medical marijuana generated more than $4.2 billion in revenue in the U.S. in 2015, according to ArcView Market Research, and they forecast it will surpass $10 billion by 2020, as regulations continue to loosen and patient access increases.
Investors interested in marijuana have a number of opportunities to participate in the sector's growth. The MJIC Marijuana Global Index, the industry's principal composite, includes 167 public companies, however the vast majority of those companies are service providers - greenhouse growers, security, extraction, edible producers, etc. Just a dozen companies in the Marijuana Global Index are actually involved in the research and development of cannabis-based pharmaceuticals.* Most investors are familiar with GW Pharmaceuticals, the only public company that has secured FDA approval for clinical trials, but there are other companies worth examining as well. Following is a listing of the medical dozen, and over the following weeks I will provide more in-depth review of each.
*Note -- two other companies included in the index- Insys Therapeutics Inc. and Zynerba Pharmaceuticals Inc. - are categorized as medical research companies, however they work with synthetic cannabinoids, and thus have not been included here.
Name
Symbol
Location
Disclosed Focus
Cannabics Pharmaceuticals Inc
CNBX
US/Israel
Malignancies
Cannabis Science Inc
CBIS
Colorado
Skin Cancers, HIV-AIDS, Neurological Disorders
Cara Therapeutics Inc
CARA
Connecticut
Pain, Inflammation and Pruritus
GrowBLOX Sciences Inc
GBLX
Nevada
Neurological and other Diseases
GW Pharmaceuticals Plc
GWPH
United Kingdom
MS Spasticity, Cancer Pain, Childhood Epilepsy
InMed Pharmaceuticals Inc
IMLFF
Canada
Dermatology and Ocular Disease
Nemus Bioscience Inc
NMUS
California
Glaucoma, MS Spasticity, Anxiety, Epilepsy, Methicillin-resistant Staphylococcus aureus (MRSA)
OWC Pharmaceutical Research Corp
OWCP
Israel
Psoriasis, Multiple Myeloma, Fibromyalgia
Oxis International Inc
OXIS
Florida
Targeting multiple myeloma, triple-negative breast cancer, non-Hodgkin's lymphoma
PharmaCyte Biotech Inc
PMCB
Maryland
Pancreatic cancer, breast cancer and diabetes
United Cannabis Corp
CNAB
Colorado
Nervous system, immune system, cancer
Verde Science Inc
VRCI
Texas
Huntington's Disease.
Conclusion
Regulations have significantly restricted medical marijuana research in the United States, but there is a small universe of institutions and companies that are making progress by taking a clinical approach to develop cannabis-based pharmaceuticals. Investors should expect mid-term sector growth as easing regulation lowers the barrier to entry for new participants, and the mounting scientific evidence mitigates the risk associated with product development. In the nearer term, there are a limited number of public vehicles for investors interested in true research into medical marijuana. If these companies can maintain their head-start within the industry they offer investors the opportunity for substantial growth in value.
03/24/16 Cannabis Science Negotiates a Total 360,000 Sq. Ft. Licensed Cannabinoid Grow and Formulation Processing in Nevada, Including Facilities for Educational and Medical Clinic and Laboratory for Drug Development Programs Targeting Multiple Critical Ailments
COLORADO SPRINGS, CO -- (Marketwired) -- 03/24/16 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced the Company has negotiated a major new drug development and facilities deal in the State of Nevada. The premises include an approximately 360,000 sq. ft. licensed cannabinoid grow and a separate formulation processing operation in Nevada. The transaction includes access to a separate educational and research facility for its drug development programs targeting critical ailment research initiatives.
All parties involved are motivated and excited to get this landmark deal underway. It gives the Company and its investor partners access to over 360,000 sq. ft. of fully-licensed land for cannabis grow operations and full access to an educational, laboratory, and medical clinic location for formulation processing and further critical ailment research.
"The goal is to bring our cannabinoid formulations across the country and internationally 'much faster' and more efficiently, and, in addition, to improve the Company's output capacity from a manufacturing standpoint. Sometimes opportunity just falls in your lap when you persevere in 'doing the right thing.' So now we move forward with this massive deal, which covers a large amount of land. We at Cannabis Science are so excited to see our widespread rollout strategy starting to come to fruition. This Nevada opportunity was a complete surprise as we were more focused on targeting California expansions; however, of course when new and fortuitous circumstances present themselves, you must be fluid, open and respond accordingly. This is what we did. The added capacity this development deal and others like it provides should allow us to rapidly move into a much larger development and production capacity, to continue the advancement of our drug development programs while we provide our important formulations to patients in need sooner and in greater geographic areas," stated Cannabis Science President & CEO, Co-Founder Raymond C. Dabney.
This added capacity will allow the Company to further its drug development programs more quickly. The Company has targeted current success with a few critical ailments including Cancer, PTSD, HIV/AIDS, Autism, and Neurological disorders, utilizing and monitoring different cannabinoid formulations and delivery modules. The Company will have a much wider base to work from by expanding into the State of Nevada, drawing another very large targeted medical consumer base.
"We have a few more landmark growth agreements underway, such as our California initiatives that are advancing nicely. The Company has more watershed operational changes to announce upon completion. We have a few more pleasant surprises to compound our growth and solidify our position in this outstanding cannabis-based pharmaceutical industry growth curve. We understand our position and we know what needs to get done. We are excited, we are motivated, and we are on the move, in the right direction. We look forward to keeping everyone up to date with all our progress. Again we wish to thank our shareholders for their continued support along this amazing path," concluded Mr. Dabney.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Cannabis Science Inc.
Teresa Misenheimer
Investor Relations
teresa@cannabisscience.com
Tel: 813-500-7332
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 310.650.3788
Cannabis Science, Inc.
Mr. Robert Kane
Director & CFO
info@cannabisscience.com
Tel: 1.888.889.0888
Source: Cannabis Science, Inc.
CBIS Medium Term Indicators Average:100% Buy
http://www.barchart.com/opinions/stocks/MCIG
03/18/16 Positive Cannabinoid Testing Data in California Prompts Cannabis Science Lab Expansions for IGXBio's GenePro FDA Investigational New Drug (IND) Number 015982 for Further Drug Development to Identify & Develop Agonist Cannabinoids for GenePro
LOS ANGELES, CA -- (Marketwired) -- 03/18/16 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines announces that it is expanding its California clinical drug development operations to work with its partner IGXBio, Inc. in developing effective therapeutics using IGXBio's Immuonotherapy (GenePro®, also referred to as ?4SHIVKU2) FDA Investigational New Drug (IND). Number 015982.
GenePro® is an investigational DNA immunotherapy sponsored by IGXBio and would be considered a biologic. The Cannabis Science partnership is working to identify and develop agonist cannabinoids and IGXBio's GenePro®.
GenePro® is a deoxyribonucleic acid (DNA) plasmid vaccine expressing simian immunodeficiency virus (SIV) and human immunodeficiency virus (HIV) proteins, which is administered by electroporation (EP). This FDA IND supports a biologic and device combination product.
HIV uses our immune system to infect healthy immunogenic cells and increase the opportunity of these cells to spread. HIV-1 proteins (gp120, Tat -- the transactivator of transcription, Vpr, and Nef) are released from infected cells throughout the course of infection and create an ongoing HIV disease burden in a number of tissues, including the central nervous system (CNS), resulting in toxicity and damage, regardless of ART.
A substantial number of individuals with HIV disease suffer brain impairment such as HIV-1 associated cognitive impairment (HAND) and dementia. Many standard anti-retroviral drugs cannot cross the blood-brain barrier (BBB) and therefore they have no effect on HIV infection in the brain.
"To further cement our foothold in the substantial pharmaceutical drug development industry, we expect our IGXBio, GenePro® drug development program to be a major pharmaceutical success. Program specific details are underway and we will update progress and results as they come in," stated Dr. Allen Herman, Cannabis Science Inc., Chief Medical Officer (CMO).
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
IGXBio
Mr. Jim Laufenberg
President and CEO
Direct: 1.888.744.9246
info@igxbio.com
Cannabis Science, Inc.
Allen A. Herman, M.B., Ch.B., Ph.D.
Chief Medical Officer, SAB & IGAB Member
Medium Term Indicators Average: 75% Buy
http://www.barchart.com/opinions/stocks/MCIG
03/18/16 Positive Cannabinoid Testing Data in California Prompts Cannabis Science Lab Expansions for IGXBio's GenePro FDA Investigational New Drug (IND) Number 015982 for Further Drug Development to Identify & Develop Agonist Cannabinoids for GenePro
LOS ANGELES, CA -- (Marketwired) -- 03/18/16 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines announces that it is expanding its California clinical drug development operations to work with its partner IGXBio, Inc. in developing effective therapeutics using IGXBio's Immuonotherapy (GenePro®, also referred to as ?4SHIVKU2) FDA Investigational New Drug (IND). Number 015982.
GenePro® is an investigational DNA immunotherapy sponsored by IGXBio and would be considered a biologic. The Cannabis Science partnership is working to identify and develop agonist cannabinoids and IGXBio's GenePro®.
GenePro® is a deoxyribonucleic acid (DNA) plasmid vaccine expressing simian immunodeficiency virus (SIV) and human immunodeficiency virus (HIV) proteins, which is administered by electroporation (EP). This FDA IND supports a biologic and device combination product.
HIV uses our immune system to infect healthy immunogenic cells and increase the opportunity of these cells to spread. HIV-1 proteins (gp120, Tat -- the transactivator of transcription, Vpr, and Nef) are released from infected cells throughout the course of infection and create an ongoing HIV disease burden in a number of tissues, including the central nervous system (CNS), resulting in toxicity and damage, regardless of ART.
A substantial number of individuals with HIV disease suffer brain impairment such as HIV-1 associated cognitive impairment (HAND) and dementia. Many standard anti-retroviral drugs cannot cross the blood-brain barrier (BBB) and therefore they have no effect on HIV infection in the brain.
"To further cement our foothold in the substantial pharmaceutical drug development industry, we expect our IGXBio, GenePro® drug development program to be a major pharmaceutical success. Program specific details are underway and we will update progress and results as they come in," stated Dr. Allen Herman, Cannabis Science Inc., Chief Medical Officer (CMO).
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
IGXBio
Mr. Jim Laufenberg
President and CEO
Direct: 1.888.744.9246
info@igxbio.com
Cannabis Science, Inc.
Allen A. Herman, M.B., Ch.B., Ph.D.
Chief Medical Officer, SAB & IGAB Member
You have no idea....CBIS....